DAFTAR PUSTAKA

Abdollahi, M.R., Gaunt,T.R., Syddall,H.E., Cooper,C., Phillips,D.I.W., Ye,S., and Day,I.N.M., 2005, Angiotensin II type 1 Receptor gene polymorphism: Anthropometric and Metabolic Syndrome Traits. *JMG*, 42 : 396–401.

Alberti, K.G.M., Zimmet,P., Defronzo, R.A., 1997, *International Textbook of Diabetes Mellitus*. Second Edition. John Willey and Sons.

Alhosaini, H., 2006, *Endothelial Dysfunction & Diabetes Mellitus. Arch Int Med.*

American Diabetes Association, 2007, Standards of Medical Care in Diabetes-2007, *Diabetes Care*, 30 [Suppl 1], S4 – S41.

American Diabetes Association, 2004, Diagnosis and Classification of Diabetes mellitus. *Diabetes Care*, 27 [Suppl 1], S5 – S10.

American Diabetes Association, 2004, Nephropathy in Diabetes. *Diabetes Care*, 27 (Suppl 1), S79 – S83.

Andersen, S., 2004. Angiotensin II Receptor Blockade in Diabetic nephropathy. *Dan Med Bull*, 51 : 274 – 294.

Bagby, S.P., Lebard, L.S., Luo, Z., Ogden, B.E., Corless,C., Mcpherson, E.D., and Speth, R.C., 2002, ANG II AT1 and AT2 Receptors in Developing Kidney of Normal Microswine. *Am J Physiol Renal Physiol* 283: F755 – 764.

Balasubramanyam, M., Rema, M., Premanand, C., 2002, Biochemical and Molecular Mechanism of Diabetic Retinopathy. *Current Science*, 83 (12), 1506 – 1514.

Baudin, B., 2005, Polymorphism in Angiotensin II Receptor Genes and Hypertension. *Exp Physol,* 90(3) : 277-282.

Bloomgarden, Z.T., 2007, Diabetes and Obesity. *Diabetes Care*, 30 (12), 3145 – 3151.

Brownlee, M., 1997, Glycation of Macromolecules, dalam *International Textbook of Diabetes Mellitus*, Volume 1, second ed. John Wiley & Sons Ltd, England, hal 743 – 755.

Brownlee, M., 2005, The Pathobiology of Diabetic Complications A Unifying Mechanism. *Diabetes*, 54, 1615 – 1625.

Buraczynska, M., Ksiazek, P., Drop, A., Zaluska, W., Spasiewicz, D., 2005. Genetic Polymorphism of the Renin – Angiotensin System in End Stage Renal Disease. *Nephrol Dial Transplant* 21 : 979 – 983.

Charo, I. F., and Taubman, M. B., 2004, Chemokines in the Pathogenesis of Vascular Disease. *Citrc Res*. 95 : 858 -866.

Chiu, K.C., 2000, Diabetes Mellitus. *Diabetes Care*, 23 ; 1353-1358.

Corvol, P., and Jeunemaitre, X., 1997, Molecular Genetics of Human Hypertension: Role of Angiotensinogen. *Am J Endocrin*, 18 (5) : 662 – 667.

Craig, K. J., Donovan, K., Munnery, M., Owens, D. R., Williams, J. D., and Phillips, A. O., 2003. Identification and Management of Diabetic Nephropathy in the Diabetes Clinic. *Diabetes Care* : 1806 – 1811.

Crisan, D., and Carr, J., 2000, Angiotensin I Converting Enzyme, Genotype and Disease Associations. *J Mol Diagnostics*, 2: 3, 105 –115.

Cooper, M.E., 2004, The Role of the Renin Angiotensin Aldosteron System in Diabetes and its Vascular Complications. *Am J Hypertens,* 17 : 16S – 20S.

Devlin,T.M., 2006, *Textbook of Biochemistry With Clinical Correlations*, 6th edition, Wiley-Liss, Canada.

Dolence, K., 2004, Diabetes Mellitus : Pathogenesis and Treatment Strategies. *J Med Chem*. 47 : 4113 – 4117.

Ferder, L., Inserra, F., Martinez, 2006, Inflammation and the metabolic Syndrome : Role of Angiotensin II and Oxidative Stress. *Curr Hypertens Rep,* 8 : 191 – 198.

Fogarti, D.G., Harron, J.C., Hughes, A.E., Nevin, N.C., Doherty, C.C., Maxwell, A.P., 1996. A Moleculer Variant of Angiotensinogen is Associated with Diabetic Nephropathy in IDDM. *Diabetes*, 45 : 1204 – 1208.

Furuichi, K., Wada, T., Iwata, Y., Kitagawa, K., Kobayashi, K., Hashimoto, H., Ishiwata, Y., Asano, M., Wang, H., Matsushima, K., Takeya, M., Kuziel, W. A., Mukaida, N., and Yokohama, H., 2003. CCR2 Signaling Contributes to Ischemia – Reperfusion in Kidney. *J Am Soc Nephrol*, 14 : 2503 – 2515.

Gardner, D.G., Shoback, D., 2004, Pancreatic Hormone & Diabetes Mellitus. *Greenspan's Basic & Clinical Endocrinology*. 8 : 661 – 744.

Glavnik, Petrovic, 2003. The Angiotensin II type 1 Receptor Mediates Renal Interstitial Content of Tumor Necrosis Factor-α in Diabetic Rat. Department

of Medicine, Unversity of Virginia School of Medicine, Charlottesville, Virginia 22904; and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.,144 : 2229-2233.

Gross, J.L., Azevedo, M.J., Silveiro, S.P., Canani, L.H., Caramori, M.L., and Zelmanovitz, T., 2005, Diabetic Nephropathy : Diagnosis, Prevention, and Treatment. *Diabetes Care,* 28 : 176 – 188.

Gumprecht, J., Zychma, M.J., Grzeszczak, W., Szczechowska, E.Z., and ESRD Study group, 2000, Angiotensin I – Converting Enzyme Gene Insertion/Deletion and Angiotensinogen M235T Polymorphism : Risk of Chronic Renal Failure. *Inter Soc Nephro*, 58 : 513 - 519.

Hansen, T., 2007, Microvascular Complications. *STAR Research Course Epidemiology.*

HowSay, Y., HwaLing, K., Duraisamy, G., Isaac, S., and Rosli, R., 2005, Angiotensinogen M235T gene variants and its association with essential hypertension and plasma renin activity in Malaysian subjects: A case control study. *BMC Cardiovasc Disorders*, 5 : (7)1 – 10.

Kanwar, Y., Wada, J., Sun, L., Xie, P., Wallner, E., Chen, S., Chugh, S., Danesh, F., 2008. Diabetic Nephropathy : Mechanisms of Renal Disease Progression. *Soc Exp Biol and Med.* 233 : 4 – 11.

Koopman, R.J., Mainous, A.G., Diaz, V.A., Geesey, ME, 2005, Changes in Age at diagnosis of Type 2 Diabetes Mellitus in the United States, 1988 to 2000, *Ann Fam Med*, 3 (1) 60 – 63.

Kuo, L., Hung Wang, C., I yang, N., Wen Cheng, C., Hui Liu, M.,Yi Chen, S., Yi wang, S., Jui Hung, M., Cherng jin, W., 2008, Relation between M235T Polymorphism of the Angiotensinogen Gen and CAD in Taiwanese : An Angiography-Controlled Study. *Acta Cardiol Sin,* 24 : 75 – 79.

Laragh, J.H., 1989, Regulation of Endothelium. *New Front Cardiovasc Ther*, 83–116.

Lee, K.W., 2008, DM Nephropathy. Renal Div. Dept. of Internal Medicine Chungnam National University Hospital.

Lemeshow, S., Hosmer, D.W., dan Klar, J., 1997, *Besar Sampel dalam Penelitian Kesehatan*, Edisi Bahasa Indonesia, Gadjah Mada University Press, Yogyakarta.

Lin, J., Hu, F.B., Qi, L., Curhan, G.C., 2009. Genetic Polymorphism of Angiotensin II Type I Receptor and Angiotensinogen and Risk of Renal

Dysfunction and Coronary Heart Disease in Type II Diabetes Mellitus. *BMC Nefrology, 1 – 8.*

Lin, T.H., Chiu, H.C., Lee, Y.T., Su, H.M., Voon, W,C., Liu, H.W., Lai, W. T., Sheu, S.H., 2007. Association Between Functional Polymorphisms of Renin – Angiotensin System, Left Ventricular Mass, and Geometry Over 4 Years in a Healthy Chinese Population Aged 60 Years and Older. *J Gerontol,* 10 : 1157 – 1163.

Mondry, A., Loh, M., Liu, P., Ling Zhu, A., Nagel, M., (2005), Polymorphism of the Insertion / Deletion ACE and M235T AGT Genes and Hypertension : Suprising New Finding and Meta-Analysis of Data, *BMC Nephrology*, 6 : 1 – 11.

Morrisen, 2007. Atherosclerosis. WWAMI Medical Program, MSU

Morrissey, J., 2006. Diabetes : Integration of Metabolism Medical Biochemistry.

Murray, R.K., Granner, D.K., and Rodwell, V.W., 2003, *Harper's Illustrated Biochemistry*, 25th edition, Mc Graw Hill Companies, USA.

Murray, R.K., Granner, D.K., and Rodwell, V.W., 2006, *Harper's Illustrated Biochemistry*, 27th edition, Mc Graw Hill Companies, USA.

Ohtani, R., Yayama, K., Takano, M., Itoh, N., and Okamoto, H., 1992, Stimulation of Angiotensinogen Production in Primary Cultures of Rat Hepatocytes by Glukokortikoid, Cyclic Adenosine 3',5'-Monophosphate and Interleukin-6. *J Am Soc for Endocrin*, 130 : 1331 – 1337.

Oliverio, M.I., and Coffman, T.M., 2000, Angiotensin II Receptor Physiology Using Gene Targeting. *J Am So Physiol*, 15 : 171 – 175.

Onna, M. V., Kroon, A. A., Houben, A. J., Koster, D., Zeegers, M., Henskens, L., Plat, A. W., Stoffers, H. E., Leeuw, P. W., 2004, Genetic Risk of Atherosclerotic Renal Artery Disease. *J Am Heart Assoc*, 44 : 448 – 453.

Plat, A.W., Stoffers, H. E., Leeuw, P. W., Schayck, C. P., Soomers, F. L., Kester, A. D., Aretz, K., Kroon, A. A., 2009, The Association between Arterial Stiffness and the Angiotensin II Type 1 Receptor (A1166C) Polymorphism is influenced by the Use of Cardiovascular medication. *J Hypertens,* 27 : 69 – 75.

Rong, C., Cheng, C.H., Shu, K.H., Chen, C.H., Lian, J.D., Wu, M.Y., 2003, Study of the Polymorphism of Angiotensinogen, Anigiotensin-Converting Enzyme and Angiotensin Receptor in Type II Diabetes with End-Stage Renal Disease in Taiwan. *J Chin Med Assoc*, 66 : 51–56.

Russ, A.P., Maerz, W., Ruzicka, V., Stein, U., and Grob, W., 1993, Rapid Detection of the Hypertension – Association Met235 →Thr Allele of the Human Angiotensinogen Gene. *Hum Mol Genet*, 2 : 609 – 610.

Sastroasmoro, S., and Ismael, S., 2002, Dasar-Dasar Metodologi Penelitian Klinis. Fakultas Kedokteran UI, 2 : 278.

Savage, D.A., Feeney, S.A., Fogarty, D.G., and Maxwell, A.P., 1999, Risk of Developing Diabetic Nephropathy is not Associated with Synergism between Angiotensin II (Type 1) Receptor C1166 allele and poor Glycaemic Control. *Nephrol Dial Transplant*, 14 : 891-894.

Say, Y,H., 2005, Angiotensinogen M235T gene variants and its association with essential hypertension and plasma renin activity in Malaysian Subjects : A Case Control Study, *BMC Cardiovascular* 1 – 10.

Schelleman, H., Klungel, O.H., Witteman, C.M., Breteler, M.M.B., Yazdanpanah, M., Danser, A.H.J., Hofman, A., Duijn, C.M., Boer, A.D., and Stricker, B.H., 2007, Angiotensinogen M235T Polymorphism and the risk of Myocardial Infarction and Stroke Among Hipertensive Patients on ACE-Inhibitors or β-Blockers. *Europ J Hum Genet* ,15 : 478 – 484.

Schmidt, S., Giebel, R., Bergis, K.H., Strojek, K., Grzeszczak, W., Ganten, D., Ritz, E., and diabetic nephropathy study group, Angiotensinogen gene M235T polymorphism is not associated with diabetic nephropathy. *Nephrol Dial Transplant,* 11: 1755-1761.

Scrijvers, B.F., Vriese, A.S., and Flyvbjerg, A., 2004, From Hyperglicemia to Diabetic Kidney Disease : The Role of Mnetabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines, *Endocrine Reviews*, 25 (6), 971 – 1010.

Sethi, A.A., Hansen, A.T., Gronholdt, M.L.M., Steffensen, R., Schnohr, P., Nordestgaard,B.G., 2001, Angiotensinogen Mutations and Risk for Ischemic Heart Disease, Myocardial Infarction, and Ischemic Cerebrovascular Disease. *Am Soc Int Med,* 134 : 941 - 954.

Sethi, A,A., Nodestgaard, B. G., and Hansen, A. T., 2003. Angiotensin Gene Polymorphism, Plasma Angiotensinogen, and Risk of Hypertension and Ischemic Heart Disease. *Arterioscler Thromb Vasc Biol.* 23 : 1269 – 1275.

Setyono, J., Asj'ari, S,R., dan Sadewa, A.H., 2009, Polimorfisme Gena Reseptor MCP-1 (CCR2) dan RANTES (CCR5) sebagai Faktor Risiko Nefropati Diabetika pada Penderita DM tipe 2. Tesis Program Studi IKD dan Biomedis UGM. Jogjakarta.

Tarnow, L., Cambien, F., Rossing, P., Nielsen, S.F., Hansen, B.V., Ricard, S., Poirier, O.,and Parving, H.H., 1996, Angiotensin II Type 1 Receptor Gene Polymorphism and Diabetic Microangiopathy. *Nephrol Dial Transplant,* 11 : 1019 – 1023.

Tuncer, 2008, Pancreas Endocrin. *Human Patology*, 31 : 1368.

Wagner, J., Gehlen, F., Ritz, E., and Ciechanowicz, A., 1999, Angiotensin II Receptor Type 1 Gene Expression in Human Glomerulonephritis and Diabetes Mellitus. *J Am Soc Nephrol*, 10 : 545 – 551.

Wendt, T.M., Tanji, N., Guo, J., Hudson, B.I., Bierhaus, A., Ramasamy, R., Arnold, B., Nawroth, P.P., Yan, S.F., D'Agati, V.D., and Schimdt, A.M., 2003, Glucose, Glycation, and RAGE: Implications for Amplification of Cellular Dysfunction in Diabetic Nephroparthy, *Am J Pathol*, 14 : 1383 – 1395.

Wendt, T.M., Tanji, N., Guo, J., Kislinger, T.R., Qu, W., Lu, Y., Bucciarelli, L.G., Rong, L.L., Moser, B., Markowitz, G.S., Stein, G., Bierhaus, A., Liliensiek, B., Arnold, B., Nawroth, P.P., Stern, D.M., D'Agati, V.D., and Schimdt, A.M., 2003, RAGE Drives the Development of Glomerulosclerosis and Implicates Podocyte Activation in the Pathogenesis of Diabetic Nephropathy, *Am J Pathol*, 162 : 1123 – 1137.

Wiecek, A., Chudek, J., and Kokot, F., 2003, Role of Angiotensin II in the Progression of Diabetic Nephropathy-Therapeutic Implications. *Nephrol Dial Transplant,* 18 [Suppl 5]: v16–v20

Wolf, G., and Ritz, E., 2003, Diabetic Nephropathy in Type 2 Diabtes Prevention and Patient Management, *J Am Soc Nephrol*, 14 : 1396 – 1405.

Woon, P., Jian, M., David, V., Lee, H.P., and Yu, M.C., 2005, Polymorphism in Angiotensin II tipe 1 Receptor and Angiotensin I-Converting Enzyme Genes and Breast Cancer Risk Among Chinese Women in Singapore. Department of Community, Occupational and Family Medicine, National University of Singapore and University of Southern California, Los Angeles, 26, 2 : 459-464.

Yoshinaga, M., Shimago, A., Koriyama, C., Nomura, Y., Miyata, K., Hashiguchi, J., and Arima, K., 2004, Global Drug Development. *Int J Obesity*, 4 : 494 – 499.

Yulianti, E., Asj'ari, S,R., dan Sadewa, A.H., 2009, Polimorfisme Gena *Transforming Growth Factor β 1* (TGF β 1) sebagai Faktor Risiko Terjadinya Nefropati Diabetika pada Penderita Diabetes Mellitus Tipe 2. Tesis Program Studi IKD dan Biomedis UGM. Jogjakarta.

Zychma, 2000, Angiotensinogen M235T and Chymase Gene CMA/B Polimorphysms are not associated with Nephropathy in Type II Diabetes. *Nephrol DialTransplant*, 15 : 1965 – 1970